TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04940741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator without active ingredient
Study: NCT06198504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol using end-tidal oxygen monitoring during preoxygenation before intubation
Description: According to previous studies a target of EtO2 ≥ 90% is proposed to trigger RSI and intubation. If this target is judged impossible to achieve and/or there is an imperative need to interrupt the pre-oxygenation phase, the operator is free to continue the procedure according to current recommendations.~Before the start of the inclusions, a training session on the use of the module will be organized with a reminder of the recommendations.~During the procedure, preoxygenation modalities and duration, achieved EtO2 level, conduction of the induction and intubation, minimum SpO2 and occurrence of complications will be recorded.~The procedure will stop ten minutes after completion of the orotracheal intubation procedure (defined as inflation of the balloon,clinical and capnography control).
Study: NCT05664971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection
Description: 200mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Study: NCT06191016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vagal nerve stimulation
Description: Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation
Description: Experimental group will receive noninvasive vagal nerve stimulation (nVNS) in addition to prescribed medications

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham vagal nerve stimulation
Description: control will receive sham stimulation to vagal nerve along with prescribed medications

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham vagal nerve stimulation
Description: control will receive sham stimulation to vagal nerve along with prescribed medications
Study: NCT05664971

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg via IV infusion once every 3 weeks;JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 or 75mg/m2 via IV infusion on Day 1 of a 21-day cycle, which may be maintained until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles; Subjects who have disease progression after 4 cycles may continue to receive maintenance treatment with pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175mg/m2 via IV infusion on Day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2 via IV infusion on Days 1, 2, and 3 of a 21-day cycle for 4 cycles
Study: NCT06485882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Training
Description: Animation films are watched children about self-care and social competence
Study: NCT05134012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [O-15]-Water PET Myocardial Perfusion Imaging (MPI)
Description: \[15-O\]-H2O injection is a novel PET imaging agent labeled with the radioisotope \[15-O\] administered as an intravenous (IV) injection. Participants will receive \[15-O\]-H2O treatment twice as a part of a single day imaging session. All participants will receive two IV boluses of \[15-O\]-H2O injection in a peripheral vein; one at rest and one during pharmacological stress.
Study: NCT05124613

Intervention type: OTHER
Intervention: Survey
Description: Information collected and stored in Survey:~* Type of knee surgery the patient is waitlisted for~* Demographics: age, sex, recent weight gain~* Validated and bespoke questions:~  1. EQ-5D survey (a validated questionnaire on health)~ 2. Bespoke questions on knee pain today~ 3. Bespoke questions on knee function today~ 4. Bespoke questions on change in knee pain since being waitlisted for surgery~ 5. Bespoke questions on change in knee function since being waitlisted for surgery~ 6. Bespoke questions on coping mechanisms patients use to manage symptoms~ 7. Bespoke questions on what support they would find beneficial whilst they wait for their surgery~ 8. Three bespoke questions about COVID-19 (Have they ever tested positive/Has the pandemic changed their mind about wanting surgery/Has the perception of their knee pain and function changed since the first lockdown was introduced?)
Study: NCT04738201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive thumb exercises.
Description: Exercises for recognition of thumb position and thumb force sense.
Study: NCT04781998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide 3 mg (Saxenda®) once-daily
Description: Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
Study: NCT05224752

Intervention type: OTHER
Intervention: Online Survey
Description: Online survey void of individual traceable identifiers, and launched via the Survey Monkey® portal
Study: NCT06336681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2Fit Device
Description: The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PrO2Fit Device
Description: The flow-resistive protocol using the device requires participants to maximally inhale as hard as they can and as long as they can against a small leak (2mm diameter hole) until task failure. This records maximum inspiratory pressure (MIP) and sustained maximal inspiratory pressure (SMIP) values which will be recorded and the best is chosen for the software template by the participant to continue their training session (previously described in arm/group description). The use of the device occurs three times a week, and used for 6-8 weeks.
Study: NCT04708340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rejuveinix (RJX) Active Comparator
Description: Active drug comprised of: ascorbic acid, magnesium sulfate heptahydrate, cyanocobalamin, thiamine, riboflavin 5' phosphate, niacinamide, pyridoxine, calcium d-pantothenate, and sodium bicarbonate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: 0.9% Sodium Chloride in Water for Injection a.k.a. Normal Saline for injection
Study: NCT04738201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive thumb exercises.
Description: Exercises for recognition of thumb position and thumb force sense.
Study: NCT04778670

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI CAD
Description: The Lunit INSIGHT MMG will be used as the AI CAD in our study. Initially, version 1.6.1.1 will be installed. The software version will be continuously updated with subsequent software releases, after confirming in a historic calibration dataset that the performance is improved. The operating point will be set based on a historic calibration dataset to attain a joint sensitivity of breast cancer detection of AI and first reader which is 2% higher than for first and second reader.
Study: NCT06049940

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational tetanus vaccine, adsorbed
Description: The investigational vaccine was manufactured by Sinovac Life Sciences Co., Ltd. There is not less than 40IU tetanus toxoid in 0.5ml per dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control tetanus vaccine, adsorbed
Description: The control tetanus vaccine, adsorbed was manufactured by Chengdu Olymvax Biopharmaceuticals Inc.There is not less than 40IU tetanus toxoid in 0.5ml per dose.
Study: NCT04757480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Erector Spinae plane Block (ESB)
Description: Will receive (20ml) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the eighth thoracic segment (T8).
Study: NCT05352321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: for induction chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: for induction chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: for induction and concurrent chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: for induction and concurrent chemotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: regular intensity-modulated radiotherapy
Description: in active comparator arm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: in experimental arm

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Target-reduction intensity-modulated radiotherapy
Description: in experimental arm
Study: NCT05734014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationship
Description: The feasibility study includes a one-group pre/post intervention that includes 10-hour long sessions with youth to promote healthy relationship knowledge, volition, and communication skills. Elders and near-peer (young adults) will assist during these sessions sharing advice and serving as role models for youth. In addition, to promote the connectedness between youth and their community, there are 3 monthly clan feeds.
Study: NCT06516146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention will involve online (via University of British Colombia (UBC) Zoom videoconferencing) 1-hour moderate to high intensity exercise classes 3 times a week for 6 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The intervention will involve 15 minute guided mediation following exercise classes as well as mindfulness classes.~Mindfulness classes will consist of 1.5 hour Mindfulness Based Stress Reduction (MBSR) classes for the first 2 months, followed by 1 month of 1 hour bi-weekly discussions and practice, then MBSR 2.0 for months 4 and 5, and 1 hour bi-weekly discussions and practice for the remaining month of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The intervention will involve biweekly 1-hour nutrition and cooking classes with a dietician.
Study: NCT05020834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: Functional Electrical Stimulation Group received 1.5 hours of conventional physical therapy program /session - 3 sessions weekly - three successive months + 1/2 hour of the gait training program with functional electrical stimulation /session - 3 sessions weekly - three successive months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTogs Orthotic Undergarment
Description: TheraTogs Arm The participating children worn TheraTogs orthotic undergarment and strapping as preparatory stage without application of any exercise program with gradually increasing the worn time till reaching the 8 hours per day.
Study: NCT06493786

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body odor samples
Description: Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion.

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body odor samples
Description: Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion.

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body odor samples
Description: Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion.

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body odor samples
Description: Skin odor is collected using polymer sticks, placed in contact with the skin for approximately 1 hour.~In this study, odor collection will be carried out on the thigh, forearm, armpit, neck and, if applicable, on the cancerous lesion.
Study: NCT04839458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Prescale II
Description: The participant will bite Dental Prescale II for about 3 seconds, using a force for  chewing beef . And the Dental Prescale II will be taken out from the mouth. Then the trial is end.
Study: NCT06125184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressor test
Description: Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressor test
Description: Mean arterial pressure will be increased from 65 mmHg to 85 mmHg to improve organ perfusion pressure.
Study: NCT04743219

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective removal to soft dentin, Biodentine
Description: Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the Biodentine group, Biodentine (Septodont) will be placed on the base of the cavity with a thickness of 2 mm.~The last step will be to perform a definitive direct resin restoration according to clinical indication.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective removal to soft dentin, No Base
Description: Carious tissue removed until its complete elimination from the lateral walls of the cavity using a round tungsten carbide bur at low speed until consistency of hard dentin around perimeter. With a manual excavator, the central cariogenic biomass will be removed, specifically the superficial part of the necrotic and demineralized caries dentin.~In the No base group, no bioactive material will be placed as a liner, the 3M Scothcbonf Universal Plus adhesive will be placed directly over the remaining dentin surface.~The last step will be to perform a definitive direct resin restoration according to clinical indication.
Study: NCT04870593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Elder informed about vaccination.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information
Description: Elder informed about vaccination.
Study: NCT05726643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistive training
Description: 5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resistive training
Description: 5 minutes warming up exercise for various parts of the body as moderately energetic walking.~5 to 10 minutes stretching exercise for (pectorals major, hamstring, hip flexors, and calf muscles) with each static stretch held for at least 20 seconds in first week and then 30 seconds for the remaining 5 weeks and this will be repeated about four times.~10 to 15 minutes strengthening exercise by using weights for lower limbs (knee extensors, hip abductors, and hip extensors) at first session for each patient. Ten repetitions maximum (10 RM) will be determined, which is the maximal weight can be lifted through the entire range of motion 10 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: Tape will be applied to each participant in the treatment group for the sartorius, rectus femoris, hamstrings, tibialis anterior, fibularis brevis, and the patella bilaterally using strips of the standard 2-inch Kinesio Tex Tape. The first and last inch of each strip will be applied without tension. The length of the strip will be applied with a 20%- 25% stretch and downward pressure to the insertion. Each of the sartorius, rectus femoris, hamstrings, tibialis anterior and fibularis brevis tapings used an I-strip. AY strip will be utilized for the patellar taping.
Study: NCT04857606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 609
Description: Single dose of AMG 609 administered as a subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo administered as a subcutaneous injection.
Study: NCT05821374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: 6 mg tablet
Study: NCT05203328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vapotherm
Description: Monitored anesthesia care with oxygen supplementation through a high-flow nasal cannula

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal canula
Description: Monitored anesthesia care with oxygen supplementation through a regular nasal cannula
Study: NCT06377436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental training
Description: Through The Dividat Senso intelligent platform, subjects will be subjected to locomotion, cognitive and sensory domain-specific exercise programs. The exercises will be of increasing difficulty. Cognitive exercises will in fact be carried out by interacting with the DIVIDAT device consisting of a monitor and a pressure-sensitive platform through weight shifts, multidirectional steps and jumps.
Study: NCT06426615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial electrodes
Description: Placement of intracranial electrodes in the cortico-subcortical system
Study: NCT05394311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sports based mental health promotion program
Description: sports related programs
Study: NCT06551571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrapartum Care Model
Description: - The Intrapartum Care Model was implemented for all primiparous pregnant women assigned to the intervention group during labor and after delivery by the researcher midwife, in accordance with the World Health Organization's positive birth recommendations